CN111164429B - 预测对fgf-18化合物反应性的炎性生物标志物 - Google Patents

预测对fgf-18化合物反应性的炎性生物标志物 Download PDF

Info

Publication number
CN111164429B
CN111164429B CN201880063173.4A CN201880063173A CN111164429B CN 111164429 B CN111164429 B CN 111164429B CN 201880063173 A CN201880063173 A CN 201880063173A CN 111164429 B CN111164429 B CN 111164429B
Authority
CN
China
Prior art keywords
fgf
treatment
metalloproteinases
cartilage
degraded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880063173.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111164429A (zh
Inventor
C·H·雷德尔
H·焦耳林
A-C·拜杰森
M·卡斯戴尔
P·奎斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN111164429A publication Critical patent/CN111164429A/zh
Application granted granted Critical
Publication of CN111164429B publication Critical patent/CN111164429B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880063173.4A 2017-09-29 2018-09-28 预测对fgf-18化合物反应性的炎性生物标志物 Active CN111164429B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194169.3 2017-09-29
EP17194169 2017-09-29
EP18169317.7 2018-04-25
EP18169317 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND

Publications (2)

Publication Number Publication Date
CN111164429A CN111164429A (zh) 2020-05-15
CN111164429B true CN111164429B (zh) 2024-08-09

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063173.4A Active CN111164429B (zh) 2017-09-29 2018-09-28 预测对fgf-18化合物反应性的炎性生物标志物

Country Status (16)

Country Link
US (2) US11467169B2 (cg-RX-API-DMAC7.html)
EP (1) EP3688468B1 (cg-RX-API-DMAC7.html)
JP (1) JP7418324B2 (cg-RX-API-DMAC7.html)
CN (1) CN111164429B (cg-RX-API-DMAC7.html)
AU (1) AU2018343980B2 (cg-RX-API-DMAC7.html)
CA (1) CA3075713A1 (cg-RX-API-DMAC7.html)
DK (1) DK3688468T3 (cg-RX-API-DMAC7.html)
ES (1) ES2918249T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220737T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058848T2 (cg-RX-API-DMAC7.html)
IL (1) IL273574B2 (cg-RX-API-DMAC7.html)
LT (1) LT3688468T (cg-RX-API-DMAC7.html)
PL (1) PL3688468T3 (cg-RX-API-DMAC7.html)
RS (1) RS63292B1 (cg-RX-API-DMAC7.html)
SI (1) SI3688468T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019063756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736723A (zh) * 2012-08-06 2015-06-24 默克专利有限公司 用于预测对fgf-18化合物的响应性的遗传标记

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
TW201536320A (zh) * 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736723A (zh) * 2012-08-06 2015-06-24 默克专利有限公司 用于预测对fgf-18化合物的响应性的遗传标记

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.S. Siebuhr et al.Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover.《Osteoarthritis and Cartilage》.2014,第22卷(第1期),第45页. *
Clinical Trial Protocol;Merck KGaA et al;Phase II Trial of Sprifermin in Knee OA;第1页 *
Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover;A.S. Siebuhr et al;《Osteoarthritis and Cartilage》;20141231;第22卷(第1期);第44-50页 *

Also Published As

Publication number Publication date
US12332250B2 (en) 2025-06-17
US20210231680A1 (en) 2021-07-29
ES2918249T3 (es) 2022-07-14
AU2018343980B2 (en) 2025-04-10
DK3688468T3 (da) 2022-06-20
JP7418324B2 (ja) 2024-01-19
CA3075713A1 (en) 2019-04-04
PL3688468T3 (pl) 2022-07-18
US20230258659A1 (en) 2023-08-17
EP3688468A1 (en) 2020-08-05
EP3688468B1 (en) 2022-03-16
WO2019063756A1 (en) 2019-04-04
CN111164429A (zh) 2020-05-15
AU2018343980A1 (en) 2020-04-02
JP2020535423A (ja) 2020-12-03
IL273574B1 (en) 2024-09-01
RS63292B1 (sr) 2022-06-30
SI3688468T1 (sl) 2022-08-31
US11467169B2 (en) 2022-10-11
LT3688468T (lt) 2022-06-27
HUE058848T2 (hu) 2022-09-28
IL273574B2 (en) 2025-01-01
HRP20220737T1 (hr) 2022-09-02
IL273574A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
JP7568614B2 (ja) 変形性関節症の治療のための富化戦略において有用なマーカー
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant